Your selections:
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
- Giovannoni, Gavin, Hawkes, Christopher H., Lechner-Scott, Jeannette, Levy, Michael, Yeh, E. Ann
The COVID-19 pandemic and the use of MS disease-modifying therapies
- Giovannoni, Gavin, Hawkes, Chris, Lechner-Scott, Jeannette, Levy, Michael, Waubant, Emmanuelle, Gold, Julian
Are you sure you would like to clear your session, including search history and login status?